179 related articles for article (PubMed ID: 34108262)
1. International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.
Vassal G; Houghton PJ; Pfister SM; Smith MA; Caron HN; Li XN; Shields DJ; Witt O; Molenaar JJ; Colombetti S; Schüler J; Stancato LF
Mol Cancer Ther; 2021 Aug; 20(8):1462-1468. PubMed ID: 34108262
[TBL] [Abstract][Full Text] [Related]
2. New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?
Houghton PJ
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1135-8. PubMed ID: 24093514
[No Abstract] [Full Text] [Related]
3. Targeted agents: how to select the winners in preclinical and early clinical studies?
Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
[TBL] [Abstract][Full Text] [Related]
4. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
5. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
6. Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.
Kumar S; Mokhtari RB; Yeger H; Baruchel S
Expert Opin Drug Discov; 2012 Nov; 7(11):1093-106. PubMed ID: 22998522
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
Serabian MA; Pilaro AM
Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
[TBL] [Abstract][Full Text] [Related]
9. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD
Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Success of Phase II Pediatric Oncology Clinical Trials.
Franshaw L; Tsoli M; Byrne J; Mayoh C; Sivarajasingam S; Norris M; Marshall GM; Ziegler DS
Oncologist; 2019 Aug; 24(8):e765-e774. PubMed ID: 30808815
[TBL] [Abstract][Full Text] [Related]
11. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
Lefer DJ; Bolli R
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
[TBL] [Abstract][Full Text] [Related]
12. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
13. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
[TBL] [Abstract][Full Text] [Related]
15. Harnessing preclinical mouse models to inform human clinical cancer trials.
Gutmann DH; Hunter-Schaedle K; Shannon KM
J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
[TBL] [Abstract][Full Text] [Related]
16. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
17. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium.
Zwaan CM; Kearns P; Caron H; Verschuur A; Riccardi R; Boos J; Doz F; Geoerger B; Morland B; Vassal G;
Cancer Treat Rev; 2010 Jun; 36(4):328-34. PubMed ID: 20231057
[TBL] [Abstract][Full Text] [Related]
18. Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Seymour LK; Calvert AH; Lobbezoo MW; Eisenhauer EA; Giaccone G;
Eur J Cancer; 2013 May; 49(8):1808-14. PubMed ID: 23428669
[TBL] [Abstract][Full Text] [Related]
19. Designing innovative therapies for neuropathic pain: preclinical and early clinical development challenges.
Höke A; Simpson DM; Freeman R
J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2():S28-9. PubMed ID: 25269739
[No Abstract] [Full Text] [Related]
20. Initial testing of topotecan by the pediatric preclinical testing program.
Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB
Pediatr Blood Cancer; 2010 May; 54(5):707-15. PubMed ID: 20017204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
